Novavax (NVAX): Un Nuevo Comienzo

Jode esto de dar news en sesion es practica nueva?

La primera vez que pasa durante la sesión jajajajaja

Jodo que paqueton le han metido ,algo por venir ??

Aprobación de la FDA. Eso es lo que ha pasado.
¿HOLD a 40$? jajajajaja
¿O mañana la tiran?

Voy a mirar el gráfico de 1minuto a ver que me dice.

Peleando la MM5 TRIMESTRAL...

Esta acción es una enfermedad.
Estoy muy enganchado.

¿Algún consejo para quitarme esta droga?

Deporte , trabajo y mirarla una vez al mes

382 mensajes en unos minutos 
wadafakkkkkkkkkkkkkkkkkkkkkkkk

mucha gente dentro.

Vamos revienta ya esos 8!!!!!!!!!

No puedo tio, no puedo. Te lo juro.
Pero no la toco. Me da igual todo. Exactamente igual.
La miro cada minuto, es una puta droga.

Pero no venderé jamás hasta ver a los putos venenos de pfizer y moderna fuera del mercado.
He hecho un juramento.

Quedarse dentro desde abajo (desde donde ya estamos) y no tocarla hasta un precio razonable por arriba. 
Nada de entrar y salir e intentar timearla.

De esta forma se mira igual, pero mucho menos y algunos dias te olvidas. Siempre que te ciñas a la estrategia.
Yo desde hace 10 meses que la tengo, ni una sola vez he vendido

Jajajajaja

Y PRRRRRRRRRRRRRRRRRRRRRR


https://ir.novavax.com/press-releases/2023-10-03-Novavax-2023-2024-COVID-19-Vaccine-Now-Authorized-and-Recommended-for-Use-in-the-U-S

Todo el mismo día.
La primera vez que esto pasa.

Pero la cotización llega 8 y se desinfla.

Malo, malo..

Escribirán libros sobre cómo de manipulada ha estado esta acción:

Volumen. Sube a todo trapo, para luego ir soltando papel poquito a poco. No me gusta nada.

La PR es muy muy muy POTENTE:


 

GAITHERSBURG, Md., Oct. 3, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, Novavax's vaccine has also been included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on September 12, 2023.

Doses will be available nationwide at thousands of locations, including national and local retail pharmacies and physicians' offices, following the Center for Biologics Evaluation and Research release of vaccine batches, expected in the coming days.

"COVID-19 is once again on the rise with infections and hospitalizations increasing, so it's important that individuals get vaccinated to protect themselves and their loved ones," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Novavax's authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine."

The EUA was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and XBB.1.16.6 as well as robust CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.1,2